Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Biologics

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1480554

Cover Image

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1480554

Small Molecule Drug Discovery

PUBLISHED:
PAGES: 184 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 4950
PDF (Global License to Company and its Fully-owned Subsidiaries)
USD 14850

Add to Cart

Description

Table of Contents

Global Small Molecule Drug Discovery Market to Reach $52.4 Billion by 2030

The global market for Small Molecule Drug Discovery estimated at US$36.1 Billion in the year 2023, is expected to reach US$52.4 Billion by 2030, growing at a CAGR of 5.5% over the analysis period 2023-2030. OncologyTherapeutic Area, one of the segments analyzed in the report, is expected to record a 6.7% CAGR and reach US$22.6 Billion by the end of the analysis period. Growth in the Central Nervous System Therapeutic Area segment is estimated at 5.9% CAGR for the next 7-year period.

The U.S. Market is Estimated at $11 Billion, While China is Forecast to Grow at 5.1% CAGR

The Small Molecule Drug Discovery market in the U.S. is estimated at US$11 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$9.1 Billion by the year 2030 trailing a CAGR of 5.1% over the analysis period 2023 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 5.4% and 4.2% respectively over the 2023-2030 period. Within Europe, Germany is forecast to grow at approximately 4.4% CAGR.

Introducing Our Exciting New Report Features for 2024

Full access to influencer engagement stats

Free access to our digital archives & "MarketGlass" research platform. Our proprietary MarketGlass platform is fully enabled to unlock creativity and market knowledge of domain experts worldwide in a cohesive and collaborative manner. Our state-of-art tools bring world class market perspectives while protecting participants' privacy and identity. Numbers, statistics and market narrative in the report are based on fully curated insights shared by domain experts and influencers in this space.

Opportunity to engage with interactive questionnaires that come with real-time data simulator tools & bespoke report generation capabilities

Full client access to peer collaborative and interactive platform for cross-enterprise smart exchange of ideas

Complimentary report updates for one year

Competitor coverage with global market shares of major players

Player market presence analysis (Strong/Active/Niche/Trivial) across multiple geographies

Access to curated YouTube video transcripts of domain experts/influencer interviews, podcasts, press statements and event keynotes

What to Expect from the Global Economy in 2024

Edgy geopolitics, and economic instability caused by monetary policy tightening and ensuing higher interest rates will create a tumultuous landscape for 2024. Several factors will continue to exert pressure on the path to recovery including hostilities in the Middle East and increasingly common climate disasters. Among the risks, several positives are also taking shape such as growing signs of disinflation and easing of anxiety over stubborn inflation, supply chain normalization and price moderation despite volatility in energy costs. Elections across several G21 jurisdictions, notably in India and the United States, will have potential ramifications for capital flows and investment strategies. While India emerges as a compelling destination in the global investment landscape, U.S, based tech firms will continue to dominate, fueled by a dynamic ecosystem of talent and capital. Tech opportunities in Silicon Valley and beyond remain attractive for investors seeking high-growth prospects supported largely by a resilient albeit slowing domestic economy and conducive regulatory environment. Europe will continue to battle tight monetary policy and recession risks with U.K. having the most challenging outlook and running the greatest risk of recession in 2024. China remains a wild card with hope for growth in the country underpinned by government spending and improvements in consumer spending. The volatile environment will offer both opportunities and challenges for investors and businesses alike. Embracing volatility as a catalyst for growth together with agility and strategic foresight in navigating investment decisions will remain important for survival.

Select Competitors (Total 21 Featured) -

  • AstraZeneca PLC
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Pfizer, Inc.
  • Teva Pharmaceutical Industries Ltd.
Show more
Product Code: MCP14780

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Small Molecule Drug Discovery - Global Key Competitors Percentage Market Share in 2024 (E)
    • Global Economic Update
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Small Molecule Drug Discovery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Small Molecule Drug Discovery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 3: World 16-Year Perspective for Small Molecule Drug Discovery by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 6: World 16-Year Perspective for Oncology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Central Nervous System by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Central Nervous System by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 9: World 16-Year Perspective for Central Nervous System by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Cardiovascular by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 11: World Historic Review for Cardiovascular by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 12: World 16-Year Perspective for Cardiovascular by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for Anti-Infective by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 14: World Historic Review for Anti-Infective by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 15: World 16-Year Perspective for Anti-Infective by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Immunological by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 17: World Historic Review for Immunological by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 18: World 16-Year Perspective for Immunological by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 19: World Recent Past, Current & Future Analysis for Other Therapeutic Areas by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 20: World Historic Review for Other Therapeutic Areas by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 21: World 16-Year Perspective for Other Therapeutic Areas by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Target Id/Validation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 23: World Historic Review for Target Id/Validation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 24: World 16-Year Perspective for Target Id/Validation by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 25: World Recent Past, Current & Future Analysis for Hit Generation and Selection by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 26: World Historic Review for Hit Generation and Selection by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 27: World 16-Year Perspective for Hit Generation and Selection by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 28: World Recent Past, Current & Future Analysis for Lead Identification by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 29: World Historic Review for Lead Identification by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 30: World 16-Year Perspective for Lead Identification by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 31: World Recent Past, Current & Future Analysis for Lead Optimization by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 32: World Historic Review for Lead Optimization by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 33: World 16-Year Perspective for Lead Optimization by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 34: World Small Molecule Drug Discovery Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Small Molecule Drug Discovery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 35: USA Recent Past, Current & Future Analysis for Small Molecule Drug Discovery by Therapeutic Area - Oncology, Central Nervous System, Cardiovascular, Anti-Infective, Immunological and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Small Molecule Drug Discovery by Therapeutic Area - Oncology, Central Nervous System, Cardiovascular, Anti-Infective, Immunological and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: USA 16-Year Perspective for Small Molecule Drug Discovery by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System, Cardiovascular, Anti-Infective, Immunological and Other Therapeutic Areas for the Years 2014, 2024 & 2030
    • TABLE 38: USA Recent Past, Current & Future Analysis for Small Molecule Drug Discovery by Process Phase - Target Id/Validation, Hit Generation and Selection, Lead Identification and Lead Optimization - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Small Molecule Drug Discovery by Process Phase - Target Id/Validation, Hit Generation and Selection, Lead Identification and Lead Optimization Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: USA 16-Year Perspective for Small Molecule Drug Discovery by Process Phase - Percentage Breakdown of Value Sales for Target Id/Validation, Hit Generation and Selection, Lead Identification and Lead Optimization for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Small Molecule Drug Discovery by Therapeutic Area - Oncology, Central Nervous System, Cardiovascular, Anti-Infective, Immunological and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Small Molecule Drug Discovery by Therapeutic Area - Oncology, Central Nervous System, Cardiovascular, Anti-Infective, Immunological and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: Canada 16-Year Perspective for Small Molecule Drug Discovery by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System, Cardiovascular, Anti-Infective, Immunological and Other Therapeutic Areas for the Years 2014, 2024 & 2030
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Small Molecule Drug Discovery by Process Phase - Target Id/Validation, Hit Generation and Selection, Lead Identification and Lead Optimization - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for Small Molecule Drug Discovery by Process Phase - Target Id/Validation, Hit Generation and Selection, Lead Identification and Lead Optimization Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: Canada 16-Year Perspective for Small Molecule Drug Discovery by Process Phase - Percentage Breakdown of Value Sales for Target Id/Validation, Hit Generation and Selection, Lead Identification and Lead Optimization for the Years 2014, 2024 & 2030
  • JAPAN
    • Small Molecule Drug Discovery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 47: Japan Recent Past, Current & Future Analysis for Small Molecule Drug Discovery by Therapeutic Area - Oncology, Central Nervous System, Cardiovascular, Anti-Infective, Immunological and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Japan Historic Review for Small Molecule Drug Discovery by Therapeutic Area - Oncology, Central Nervous System, Cardiovascular, Anti-Infective, Immunological and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: Japan 16-Year Perspective for Small Molecule Drug Discovery by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System, Cardiovascular, Anti-Infective, Immunological and Other Therapeutic Areas for the Years 2014, 2024 & 2030
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Small Molecule Drug Discovery by Process Phase - Target Id/Validation, Hit Generation and Selection, Lead Identification and Lead Optimization - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Japan Historic Review for Small Molecule Drug Discovery by Process Phase - Target Id/Validation, Hit Generation and Selection, Lead Identification and Lead Optimization Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: Japan 16-Year Perspective for Small Molecule Drug Discovery by Process Phase - Percentage Breakdown of Value Sales for Target Id/Validation, Hit Generation and Selection, Lead Identification and Lead Optimization for the Years 2014, 2024 & 2030
  • CHINA
    • Small Molecule Drug Discovery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 53: China Recent Past, Current & Future Analysis for Small Molecule Drug Discovery by Therapeutic Area - Oncology, Central Nervous System, Cardiovascular, Anti-Infective, Immunological and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 54: China Historic Review for Small Molecule Drug Discovery by Therapeutic Area - Oncology, Central Nervous System, Cardiovascular, Anti-Infective, Immunological and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: China 16-Year Perspective for Small Molecule Drug Discovery by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System, Cardiovascular, Anti-Infective, Immunological and Other Therapeutic Areas for the Years 2014, 2024 & 2030
    • TABLE 56: China Recent Past, Current & Future Analysis for Small Molecule Drug Discovery by Process Phase - Target Id/Validation, Hit Generation and Selection, Lead Identification and Lead Optimization - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: China Historic Review for Small Molecule Drug Discovery by Process Phase - Target Id/Validation, Hit Generation and Selection, Lead Identification and Lead Optimization Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: China 16-Year Perspective for Small Molecule Drug Discovery by Process Phase - Percentage Breakdown of Value Sales for Target Id/Validation, Hit Generation and Selection, Lead Identification and Lead Optimization for the Years 2014, 2024 & 2030
  • EUROPE
    • Small Molecule Drug Discovery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 59: Europe Recent Past, Current & Future Analysis for Small Molecule Drug Discovery by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 60: Europe Historic Review for Small Molecule Drug Discovery by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: Europe 16-Year Perspective for Small Molecule Drug Discovery by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 62: Europe Recent Past, Current & Future Analysis for Small Molecule Drug Discovery by Therapeutic Area - Oncology, Central Nervous System, Cardiovascular, Anti-Infective, Immunological and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Europe Historic Review for Small Molecule Drug Discovery by Therapeutic Area - Oncology, Central Nervous System, Cardiovascular, Anti-Infective, Immunological and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: Europe 16-Year Perspective for Small Molecule Drug Discovery by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System, Cardiovascular, Anti-Infective, Immunological and Other Therapeutic Areas for the Years 2014, 2024 & 2030
    • TABLE 65: Europe Recent Past, Current & Future Analysis for Small Molecule Drug Discovery by Process Phase - Target Id/Validation, Hit Generation and Selection, Lead Identification and Lead Optimization - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Europe Historic Review for Small Molecule Drug Discovery by Process Phase - Target Id/Validation, Hit Generation and Selection, Lead Identification and Lead Optimization Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: Europe 16-Year Perspective for Small Molecule Drug Discovery by Process Phase - Percentage Breakdown of Value Sales for Target Id/Validation, Hit Generation and Selection, Lead Identification and Lead Optimization for the Years 2014, 2024 & 2030
  • FRANCE
    • Small Molecule Drug Discovery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 68: France Recent Past, Current & Future Analysis for Small Molecule Drug Discovery by Therapeutic Area - Oncology, Central Nervous System, Cardiovascular, Anti-Infective, Immunological and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: France Historic Review for Small Molecule Drug Discovery by Therapeutic Area - Oncology, Central Nervous System, Cardiovascular, Anti-Infective, Immunological and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: France 16-Year Perspective for Small Molecule Drug Discovery by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System, Cardiovascular, Anti-Infective, Immunological and Other Therapeutic Areas for the Years 2014, 2024 & 2030
    • TABLE 71: France Recent Past, Current & Future Analysis for Small Molecule Drug Discovery by Process Phase - Target Id/Validation, Hit Generation and Selection, Lead Identification and Lead Optimization - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 72: France Historic Review for Small Molecule Drug Discovery by Process Phase - Target Id/Validation, Hit Generation and Selection, Lead Identification and Lead Optimization Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: France 16-Year Perspective for Small Molecule Drug Discovery by Process Phase - Percentage Breakdown of Value Sales for Target Id/Validation, Hit Generation and Selection, Lead Identification and Lead Optimization for the Years 2014, 2024 & 2030
  • GERMANY
    • Small Molecule Drug Discovery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 74: Germany Recent Past, Current & Future Analysis for Small Molecule Drug Discovery by Therapeutic Area - Oncology, Central Nervous System, Cardiovascular, Anti-Infective, Immunological and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Germany Historic Review for Small Molecule Drug Discovery by Therapeutic Area - Oncology, Central Nervous System, Cardiovascular, Anti-Infective, Immunological and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: Germany 16-Year Perspective for Small Molecule Drug Discovery by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System, Cardiovascular, Anti-Infective, Immunological and Other Therapeutic Areas for the Years 2014, 2024 & 2030
    • TABLE 77: Germany Recent Past, Current & Future Analysis for Small Molecule Drug Discovery by Process Phase - Target Id/Validation, Hit Generation and Selection, Lead Identification and Lead Optimization - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Germany Historic Review for Small Molecule Drug Discovery by Process Phase - Target Id/Validation, Hit Generation and Selection, Lead Identification and Lead Optimization Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: Germany 16-Year Perspective for Small Molecule Drug Discovery by Process Phase - Percentage Breakdown of Value Sales for Target Id/Validation, Hit Generation and Selection, Lead Identification and Lead Optimization for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 80: Italy Recent Past, Current & Future Analysis for Small Molecule Drug Discovery by Therapeutic Area - Oncology, Central Nervous System, Cardiovascular, Anti-Infective, Immunological and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Italy Historic Review for Small Molecule Drug Discovery by Therapeutic Area - Oncology, Central Nervous System, Cardiovascular, Anti-Infective, Immunological and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: Italy 16-Year Perspective for Small Molecule Drug Discovery by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System, Cardiovascular, Anti-Infective, Immunological and Other Therapeutic Areas for the Years 2014, 2024 & 2030
    • TABLE 83: Italy Recent Past, Current & Future Analysis for Small Molecule Drug Discovery by Process Phase - Target Id/Validation, Hit Generation and Selection, Lead Identification and Lead Optimization - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Italy Historic Review for Small Molecule Drug Discovery by Process Phase - Target Id/Validation, Hit Generation and Selection, Lead Identification and Lead Optimization Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: Italy 16-Year Perspective for Small Molecule Drug Discovery by Process Phase - Percentage Breakdown of Value Sales for Target Id/Validation, Hit Generation and Selection, Lead Identification and Lead Optimization for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Small Molecule Drug Discovery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 86: UK Recent Past, Current & Future Analysis for Small Molecule Drug Discovery by Therapeutic Area - Oncology, Central Nervous System, Cardiovascular, Anti-Infective, Immunological and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: UK Historic Review for Small Molecule Drug Discovery by Therapeutic Area - Oncology, Central Nervous System, Cardiovascular, Anti-Infective, Immunological and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: UK 16-Year Perspective for Small Molecule Drug Discovery by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System, Cardiovascular, Anti-Infective, Immunological and Other Therapeutic Areas for the Years 2014, 2024 & 2030
    • TABLE 89: UK Recent Past, Current & Future Analysis for Small Molecule Drug Discovery by Process Phase - Target Id/Validation, Hit Generation and Selection, Lead Identification and Lead Optimization - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 90: UK Historic Review for Small Molecule Drug Discovery by Process Phase - Target Id/Validation, Hit Generation and Selection, Lead Identification and Lead Optimization Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: UK 16-Year Perspective for Small Molecule Drug Discovery by Process Phase - Percentage Breakdown of Value Sales for Target Id/Validation, Hit Generation and Selection, Lead Identification and Lead Optimization for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Small Molecule Drug Discovery by Therapeutic Area - Oncology, Central Nervous System, Cardiovascular, Anti-Infective, Immunological and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Rest of Europe Historic Review for Small Molecule Drug Discovery by Therapeutic Area - Oncology, Central Nervous System, Cardiovascular, Anti-Infective, Immunological and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: Rest of Europe 16-Year Perspective for Small Molecule Drug Discovery by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System, Cardiovascular, Anti-Infective, Immunological and Other Therapeutic Areas for the Years 2014, 2024 & 2030
    • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Small Molecule Drug Discovery by Process Phase - Target Id/Validation, Hit Generation and Selection, Lead Identification and Lead Optimization - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Rest of Europe Historic Review for Small Molecule Drug Discovery by Process Phase - Target Id/Validation, Hit Generation and Selection, Lead Identification and Lead Optimization Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: Rest of Europe 16-Year Perspective for Small Molecule Drug Discovery by Process Phase - Percentage Breakdown of Value Sales for Target Id/Validation, Hit Generation and Selection, Lead Identification and Lead Optimization for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Small Molecule Drug Discovery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Small Molecule Drug Discovery by Therapeutic Area - Oncology, Central Nervous System, Cardiovascular, Anti-Infective, Immunological and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for Small Molecule Drug Discovery by Therapeutic Area - Oncology, Central Nervous System, Cardiovascular, Anti-Infective, Immunological and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: Asia-Pacific 16-Year Perspective for Small Molecule Drug Discovery by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System, Cardiovascular, Anti-Infective, Immunological and Other Therapeutic Areas for the Years 2014, 2024 & 2030
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Small Molecule Drug Discovery by Process Phase - Target Id/Validation, Hit Generation and Selection, Lead Identification and Lead Optimization - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Small Molecule Drug Discovery by Process Phase - Target Id/Validation, Hit Generation and Selection, Lead Identification and Lead Optimization Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 103: Asia-Pacific 16-Year Perspective for Small Molecule Drug Discovery by Process Phase - Percentage Breakdown of Value Sales for Target Id/Validation, Hit Generation and Selection, Lead Identification and Lead Optimization for the Years 2014, 2024 & 2030
  • REST OF WORLD
    • TABLE 104: Rest of World Recent Past, Current & Future Analysis for Small Molecule Drug Discovery by Therapeutic Area - Oncology, Central Nervous System, Cardiovascular, Anti-Infective, Immunological and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Rest of World Historic Review for Small Molecule Drug Discovery by Therapeutic Area - Oncology, Central Nervous System, Cardiovascular, Anti-Infective, Immunological and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 106: Rest of World 16-Year Perspective for Small Molecule Drug Discovery by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System, Cardiovascular, Anti-Infective, Immunological and Other Therapeutic Areas for the Years 2014, 2024 & 2030
    • TABLE 107: Rest of World Recent Past, Current & Future Analysis for Small Molecule Drug Discovery by Process Phase - Target Id/Validation, Hit Generation and Selection, Lead Identification and Lead Optimization - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Rest of World Historic Review for Small Molecule Drug Discovery by Process Phase - Target Id/Validation, Hit Generation and Selection, Lead Identification and Lead Optimization Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 109: Rest of World 16-Year Perspective for Small Molecule Drug Discovery by Process Phase - Percentage Breakdown of Value Sales for Target Id/Validation, Hit Generation and Selection, Lead Identification and Lead Optimization for the Years 2014, 2024 & 2030

IV. COMPETITION

Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!